Pre-made Obrindatamab benchmark antibody ( Bispecific scFv with Domain Crossover, anti-CD276;CD3E therapeutic antibody, Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Obrindatamab biosimilar, Bispecific scFv with Domain Crossover, Anti-CD276;CD3E Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Obrindatamab (formerly orlotamab) was a Fc-bearing humanised bispecific dual-affinity re-targeting (DART) protein, that was being developed by MacroGenics for the treatment of solid tumours.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-386-1mg	1mg	Inquiry
GMP-Bios-ab-386-10mg	10mg	Inquiry
GMP-Bios-ab-386-100mg	100mg	Inquiry
GMP-Bios-ab-386-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Obrindatamab biosimilar, Bispecific scFv with Domain Crossover, Anti-CD276;CD3E Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 therapeutic antibody
INN Name	Obrindatamab
Target	CD276;CD3E
Format	Bispecific scFv with Domain Crossover
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	na;na
VD LC	Kappa;Lambda
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2020
Year Recommended	2021
Companies	MacroGenics
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Advanced or Metastatic solid tumours
Development Tech	na